Micron Drops From Highs With AI Tailwind Facing Earnings Bar

Micron Drops From Highs With AI Tailwind Facing Earnings Bar

New York, June 16, 2026, 12:55 ET

  • Micron Technology gave up ground after its record close. The stock was last down about 3.6% at $1,048.87.
  • Semiconductor stocks slipped following Monday’s rally, as some investors appeared to lock in profits from the strong run rather than reacting to a particular company issue. Chip names came under pressure too.
  • Micron’s fiscal Q3 earnings call on June 24 is up next, with investors looking to see if AI memory demand backs up the stock’s rally.

Micron Technology shares slid Tuesday after hitting a record high, as traders cashed in gains from the stock’s recent AI-fueled run. Shares were last at $1,048.87, off $39.12 from the previous close. The stock opened at $1,100 and moved between $1,020.20 and $1,133.00. This follows Monday’s rally, when Micron closed at a record $1,087.99 after buyers pushed memory-chip stocks higher on hopes for more AI data-center demand.

Chip stocks cooled off, with the PHLX Semiconductor Index, or SOX, falling 3.2% at midday Tuesday. The index had been down as much as 4.5% earlier. MarketWatch That’s a problem for Micron, which is seen as a riskier AI infrastructure play. The stock tends to swing hard with semiconductor sentiment, whether or not there’s news from the company itself.

Micron bulls are betting on simple math. AI servers need more DRAM—the regular memory in computers—and more HBM, the stacked, high-bandwidth memory built for newer AI chips. TD Cowen’s Krish Sankar pushed his Micron target to $1,500, RBC’s Srini Pajjuri went to $1,200, both pointing to higher memory demand and better prices. MarketWatch said the DRAM upcycle could last another five to six quarters. MarketWatch In May, Reuters said Micron’s 2026 HBM supply was already gone, and HBM4 was rolling out. Reuters After Q2, CEO Sanjay Mehrotra called the change clear: “memory has become a strategic asset for our customers.” Micron Technology

Micron faces its next earnings test on June 24. The chipmaker will report fiscal Q3 results after the bell, with its financial call set for 4:30 p.m. EDT. Analysts get a follow-up call two hours later. Micron Technology Investors are focused on whether Micron can match or top its own Q3 targets: $33.5 billion in revenue, give or take $750 million, and gross margin of around 81%. For memory makers, gross margin is a critical gauge of what kind of pricing power is in play.

Micron’s bears aren’t arguing the business is weak—it’s that the rally could be priced in already. MarketWatch points out Micron’s RSI hit 90.98. That’s a momentum signal and numbers above 70 can suggest the stock is overbought. MarketWatch Barron’s adds the shares are up more than 800% the past year, so expectations are sky-high and analysts keep lifting targets. Barron’s Micron is still drawing interest from investors betting memory shortages from AI and high margins will last through 2027. But after this kind of run, the shares don’t look cheap, and any letdown on June 24 could hit both earnings hopes and the valuation.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY IN STAGES

AerCap

NYSE: AER 95 / 100
#2 BUY ON WEAKNESS

Xylem

NYSE: XYL 93 / 100
#3 ACCUMULATE

General Dynamics

NYSE: GD 91 / 100
#4 BUY WITH LIMITS

Visa

NYSE: V 88 / 100
#5 TACTICAL BUY

IDEX

NYSE: IEX 85 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Dow Closes at Record in After-Hours as S&P 500, Nasdaq Dip on Tech Slide
Previous Story

US Stock Market Today: Live Updates 16.06.2026

Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms
Next Story

Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms